Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: A 24-week, randomized, double-blind, placebo-controlled trial.

Yuan-Di C HalvorsenAnnie L ConeryJohn Paul LockWenjiong ZhouMason W Freeman

Published in: Diabetes, obesity & metabolism (2023)

Bexagliflozin produced clinically meaningful improvement in glycaemic control, estimated glomerular filtration rate and SBP when added to metformin in a population of adults with diabetes.

Keyphrases

double blind
placebo controlled
type diabetes
clinical trial
phase iii
phase ii
study protocol
cardiovascular disease
glycemic control
open label
randomized controlled trial
metabolic syndrome
weight loss